Company Performance - Amgen's stock closed at $353.93, reflecting a +1.58% increase from the previous day, outperforming the S&P 500's gain of 0.54% [1] - Over the last month, Amgen's shares have decreased by 9%, which is worse than the Medical sector's loss of 8.43% and the S&P 500's loss of 4.71% [1] Earnings Expectations - The upcoming earnings report is expected to show an EPS of $4.74, a decrease of 3.27% compared to the same quarter last year [2] - Revenue is projected to be $8.51 billion, representing a 4.42% increase from the previous year [2] - For the full year, analysts expect earnings of $22.22 per share and revenue of $37.86 billion, indicating changes of +1.74% and +3.02% respectively from last year [3] Analyst Estimates - Recent changes to analyst estimates for Amgen are important as they reflect short-term business trends, with upward revisions indicating positive sentiment towards the company's operations [4] - The Zacks Rank system, which incorporates these estimate changes, currently rates Amgen as 3 (Hold) [6] Valuation Metrics - Amgen is trading at a Forward P/E ratio of 15.68, which is lower than the industry average of 17.97 [7] - The company has a PEG ratio of 3.47, compared to the industry average PEG ratio of 1.46 [8] Industry Context - The Medical - Biomedical and Genetics industry, which includes Amgen, ranks 146 out of over 250 industries, placing it in the bottom 41% [9] - The Zacks Industry Rank indicates that top-rated industries outperform the bottom half by a factor of 2 to 1 [9]